MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a leader in regenerative medicine, today announced positive preliminary results from its ongoing clinical trial of StrataGraft®, a universal human skin substitute being developed for the treatment of severe burns. All patients enrolled to date have avoided the need for painful autografting, the standard of care which involves transplanting skin from one part of a patient’s body to the wound site. All seven patients assessed at three months achieved complete wound closure with a single application of StrataGraft®.
